Latigo Biotherapeutics, Inc. (LTGO) SEC filings
LTGONasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 5, 2026
$13.11+0.18 (+1.39%)
Close on Nov 13, 2026Market cap $869.18MP/E –Yield 0.00%
SEC filings
5 of Latigo Biotherapeutics's most recent filings on SEC EDGAR
| Document | Form | Period | Filed | Source |
|---|---|---|---|---|
| Quarterly report | 10-Q | Sep 30, 2026 | Nov 5, 2026 | SEC EDGAR |
| Current report | 8-K | Nov 3, 2026 | Nov 5, 2026 | SEC EDGAR |
| Quarterly report | 10-Q | Jun 30, 2026 | Sep 3, 2026 | SEC EDGAR |
| Current report | 8-K | Sep 3, 2026 | Sep 3, 2026 | SEC EDGAR |
| Current report | 8-K | Aug 10, 2026 | Aug 10, 2026 | SEC EDGAR |
See a number that looks wrong?